Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 14/20 | 0.47 |
| ▸ | KCNJ3 | P48549 | 14/20 | 0.47 |
| ▸ | KCNJ5 | P48544 | 11/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225046 | 0.95 | KCNJ6 (0.48) | KCNJ6KCNJ3KCNJ5ALDH1A1RAB9A | |
| SCHEMBL1013226 | 0.86 | KCNJ6 (0.61) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL1010934 | 0.81 | KCNJ6 (0.63) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL21228045 | 0.79 | GAA (0.47) | KCNJ6KCNJ3RAB9AGAAMAPT | |
| SCHEMBL11966180 | 0.78 | KCNJ6 (0.43) | KCNJ6KCNJ3KCNJ5ALDH1A1GAA | |
| SCHEMBL13860720 | 0.78 | MAPT (0.57) | ALDH1A1RAB9ANPSR1MAPT | |
| SCHEMBL13860390 | 0.76 | KCNJ6 (0.55) | KCNJ6KCNJ3KCNJ5 | |
| SCHEMBL2852141 | 0.76 | JAK2 (0.56) | KCNJ6KCNJ3KCNJ5GAA | |
| SCHEMBL5224672 | 0.74 | RAB9A (0.48) | ALDH1A1RAB9AGAANPSR1MAPT | |
| SCHEMBL1010615 | 0.74 | MAPK14 (0.65) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288537-B2 | Azetidine derivatives as CCR-3 receptor antagonists | NOVARTIS AG (CH) | 2007-10-30 | — | — | US | disclosed |
| EP-1663966-B1 | 1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | NOVARTIS AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20070043013-A1 | 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases | LE GRAND DARREN M | 2007-02-22 | — | — | US | disclosed |
| EP-1663966-A1 | 1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | Novartis AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| WO-2005026113-A1 | 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | NOVARTIS AG (CH) | 2005-03-24 | — | — | WO | disclosed |
| EP-1487435-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003077907-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | CCR3, CCR1, CCR9 | KCNJ6 1033/4885KCNJ3 422/4885KCNJ5 1010/4885 |
| US-20070043013-A1 | 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases | CCR1, CCR3, CCR9 | KCNJ6 972/4885KCNJ3 418/4885KCNJ5 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.